TP53 and ovarian cancer: Regarding somatic mutations, in the entire population considered from the ovarian cancer TCGA dataset (N = 316), TP53 dominates over all the other genes, with a prevalence of 86.4%, followed by TTN, BRCA1, and BRCA2 to a much lower extent (Figure 6a).